WHAT IS THE MECHANISM OF ACTION OF A PROTON PUMP INHIBITOR?
21.05.2023
International Scientific Journal "Science and Innovation". Series D. Volume 2 Issue 5
Azimbegova Sitora Nodirovna
Abstract. Pariet - PPI proton pump inhibitors with the active ingredient rabeprazole, after passing through the stomach, enter the small intestine, where they dissolve, after which they first enter the liver through the bloodstream, and then penetrate the membrane of the parietal cells of the gastric mucosa. goes and there they accumulate in the secretion. tubules. Here, at acidic pH, proton pump inhibitors are activated and become tetracyclic mechanism of action of proton pump inhibitors (Maev I.V. et al.)
Keywords: proton pump inhibitor, action, mechanism, types of proton pump inhibitors
References:
1. Hagymási K., Müllner K., Herszényi L. et al. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2011;12(6):873–888. DOI: 10.2217/pgs.11.4.
2. Li X.-Q., Andersson T.B., Ahlström M., Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome p450 activities. Drug Metabolism and Disposition. 2004; 32:821–827. DOI: 10.1124/dmd.32.8.821.
3. Bakheita A.H., Al-Kahtania H.M., Albraikia S. Rabeprazole: A comprehensive profile. Profiles of Drug Substances, Excipients, and Related Methodology. DOI:10.1016/bs.podrm.2020.07.003.
4. Ward R.M., Kearns G.L. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmaodynamics. Paediatr Drugs. 2013;15(2):119–131. DOI: 10.1007/s40272-013-0012-х.
5. Gawrońska-Szklarz B., Adamiak-Giera U., Wyska E. et al. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur J Clin Pharmacol. 2012;68(9):1267–1274. DOI: 10.1007/s00228-012-1252-3.
6. Table of Pharmacogenomic Biomarkers in Drug Labeling. (Elecrtonic recourse.) URL: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling (access date: 20.12.20).
7. Relling M.V., Klein T.E., Gammal R.S. et al. The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later.Clin Pharmacol Ther. 2020;107(1):171–175. DOI: 10.1002/cpt.1651.
8. Азимбегова С. Н., Давранова А. Д. БОЛAЛAРДA 1-ТУР ҚAНДЛИ ДИAБЕТНИ ДAВОЛAШИНИ ЎЗГAРТИРИШ ВA ДИAБЕТИК РЕТИНОПAТИЯСИНИ ОЛДИНИ ОЛИШ ХУСУСИЯТЛAРИ //ЖУРНАЛ ГЕПАТО-ГАСТРОЭНТЕРОЛОГИЧЕСКИХ ИССЛЕДОВАНИЙ. – 2022. – Т. 3. – №. 2.
9. Shukhratovna N. G. et al. Analysis of the thyroid status of pregnant women in the iodine-deficient region //The American Journal of Medical Sciences and Pharmaceutical Research. – 2022. – Т. 4. – №. 01. – С. 74-78.
10. Shukhratovna N. G. et al. ASSESSMENT OF THE EFFECTIVENESS OF CARDIOPROTECTIVE DRUGS IN TREATMENT OF CHILDREN WITH DIABETIC CARDIOMYOPATHY //The American Journal of Medical Sciences and Pharmaceutical Research. – 2022. – Т. 4. – №. 01. – С. 79-83.
11. Lai T., va boshqalar. Homiladorlik davrida kislotani bostiruvchi dori vositalaridan foydalanish va bolalik astma xavfi: Meta-tahlil. Pediatriya. 2018 yil yanvar.
SCIENCE & INNOVATION